WO2015130840A3 - Treatment of resistant lesions - Google Patents

Treatment of resistant lesions Download PDF

Info

Publication number
WO2015130840A3
WO2015130840A3 PCT/US2015/017595 US2015017595W WO2015130840A3 WO 2015130840 A3 WO2015130840 A3 WO 2015130840A3 US 2015017595 W US2015017595 W US 2015017595W WO 2015130840 A3 WO2015130840 A3 WO 2015130840A3
Authority
WO
WIPO (PCT)
Prior art keywords
lesions
treatment
resistant
resistant lesions
healing
Prior art date
Application number
PCT/US2015/017595
Other languages
French (fr)
Other versions
WO2015130840A2 (en
Inventor
Anthony Phillips
Scott BANNAN
Grove MATSUOKA
Bradford DUFT
David EISENBUD
Original Assignee
Coda Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coda Therapeutics, Inc. filed Critical Coda Therapeutics, Inc.
Priority to EP15755058.3A priority Critical patent/EP3110455A4/en
Priority to CA2940648A priority patent/CA2940648A1/en
Publication of WO2015130840A2 publication Critical patent/WO2015130840A2/en
Publication of WO2015130840A3 publication Critical patent/WO2015130840A3/en
Priority to US15/247,853 priority patent/US20170056468A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Connexin protein modulation methods and compositions are provided for the healing of resistant lesions, including lesions on subjects with multiple venous leg ulcers or multiple diabetic foot ulcers, and other responder subjects. Also provided are kits and articles of manufacture comprising a connexin protein modulating agent, for example, a connexin 43 modulating agent for use in the healing of resistant lesions.
PCT/US2015/017595 2014-02-25 2015-02-25 Treatment of resistant lesions WO2015130840A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP15755058.3A EP3110455A4 (en) 2014-02-25 2015-02-25 Treatment of resistant lesions
CA2940648A CA2940648A1 (en) 2014-02-25 2015-02-25 Treatment of resistant lesions
US15/247,853 US20170056468A1 (en) 2014-02-25 2016-08-25 Treatment of resistant lesions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461944566P 2014-02-25 2014-02-25
US61/944,566 2014-02-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/020786 Continuation-In-Part WO2015139047A2 (en) 2014-02-25 2015-03-16 Treatment of resistant lesions

Publications (2)

Publication Number Publication Date
WO2015130840A2 WO2015130840A2 (en) 2015-09-03
WO2015130840A3 true WO2015130840A3 (en) 2015-11-05

Family

ID=54009775

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/017595 WO2015130840A2 (en) 2014-02-25 2015-02-25 Treatment of resistant lesions

Country Status (3)

Country Link
EP (1) EP3110455A4 (en)
CA (1) CA2940648A1 (en)
WO (1) WO2015130840A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210079406A1 (en) * 2018-04-10 2021-03-18 President And Fellows Of Harvard College Aav vectors encoding clarin-1 or gjb2 and uses thereof
CN115103710A (en) * 2019-09-30 2022-09-23 应用遗传科技公司 Adeno-associated virus (AAV) system for the treatment of hereditary hearing loss

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100279921A1 (en) * 2007-12-11 2010-11-04 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US20130079388A1 (en) * 1999-01-27 2013-03-28 Coda Therapeutics, Inc. Formulations comprising antisense nucleotides to connexins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9156896B2 (en) * 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130079388A1 (en) * 1999-01-27 2013-03-28 Coda Therapeutics, Inc. Formulations comprising antisense nucleotides to connexins
US20100279921A1 (en) * 2007-12-11 2010-11-04 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ARNOLD, S ET AL.: "Prospective, Multicenter Study Of Managing Lower Extremity Venous Ulcers", ANNALS OF VASCULAR SURGERY, vol. 8, no. 4, July 1994 (1994-07-01), pages 356 - 362, XP005940154, [retrieved on 20150602], DOI: doi:10.1007/BF02132997 *
BRYANT, R.: "Acute & Chronic Wounds; Current Management Concepts: Chapter 4: Hound Healing Physiology", REFERENCE & RESEARCH BOOK NEWS ., 2011, XP008184658, [retrieved on 20150602] *
HINES, JR., MD , EA .: "The Differential Diagnosis Of Chronic Ulcer Of The Leg.", CIRCULATION, vol. 27, no. 5, May 1963 (1963-05-01), pages 989 - 996, XP055234982, ISSN: 0009-7322, [retrieved on 20150602] *
MOSTOW, E ET AL.: "Effectiveness Of An Extracellular Matrix Graft (OASIS Wound Matrix) In The Treatment Of Chronic Leg Ulcers: A Randomized Clinical Trial.", JOURNAL OF VASCULAR SURGERY, vol. 41, no. 5, 2005, pages 837 - 843, XP004916563, ISSN: 0741-5214, [retrieved on 20150602] *
See also references of EP3110455A4 *
SHEEHAN, P ET AL.: "Percent Change In Wound Area Of Diabetic Foot Ulcers Over A 4-Week Period Is A Robust Predictor Of Complete Healing In A 12-Week Prospective Trial", DIABETES CARE, vol. 26, no. 6, 2003, pages 1879 - 1882, XP055234978, [retrieved on 20150602] *
SUSSMAN ET AL.: "Wound Care: A Collaborative Practice Manual For Health Professionals", WOUND MEASUREMENT AND PREDICTION OF HEALING, 2012, Philadelphia, XP008184648, [retrieved on 20150602] *

Also Published As

Publication number Publication date
CA2940648A1 (en) 2015-09-03
EP3110455A4 (en) 2017-10-11
WO2015130840A2 (en) 2015-09-03
EP3110455A2 (en) 2017-01-04

Similar Documents

Publication Publication Date Title
WO2017163132A3 (en) Use of umbilical cord blood derived exosomes for tissue repair
MX2017010734A (en) Combination therapy with coagulation factors and multispecific antibodies.
MX2021010528A (en) Methods and compositions for treating ulcers.
BR112018073574A2 (en) anti-cmet antibody-drug conjugates and methods for their use
EP3379999A4 (en) Mapping and quantifying blood stasis and thrombus risk in the heart
CA2899482C (en) Surgical stapling cartridge with layer retention features
MX2019015311A (en) Cannabidiolic acid esters compositions and uses thereof.
WO2015026601A3 (en) Dithiol mucolytic agents
UY33492A (en) IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
BR112019021290A8 (en) EXTENSIVE DRESSINGS
WO2018042438A3 (en) Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders
WO2016149501A3 (en) Modified therapeutic agents and compositions thereof
GT201600084A (en) (AZA) PIRIDOPIRAZOLOPIRIMIDINONAS AND INDAZOLOPIRIMIDINONAS AND ITS USE
WO2014106825A3 (en) Methods and devices for identifying improper medical reporting
MX2018002546A (en) Compositions comprising an urolithin compound.
MX2018002543A (en) Compositions comprising urolithin compounds.
WO2015148389A3 (en) Diagnosis of multiple sclerosis in human and animal subjects
AU2018262805A1 (en) Peptides for treatment of diabetes
BR112019021335A2 (en) EXTENSIBLE DRESSINGS
WO2015187727A3 (en) Molecular mammography
EP3630124A4 (en) Synthetic composition comprising oligosaccharides and its use in medical treatment.
WO2015130840A3 (en) Treatment of resistant lesions
DOP2015000175A (en) USE OF A NATURAL PEPTIDE, A DIURETIC PEPTIDE OR A VASODILATOR PEPTIDE IN THE PREPARATION OF A MEDICINAL PRODUCT TO TREAT A CARDIOVASCULAR CONDITION
WO2016102930A3 (en) Medical device for treating a vein
BR112017012911A2 (en) method for treating heart failure

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15755058

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2940648

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015755058

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015755058

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15755058

Country of ref document: EP

Kind code of ref document: A2